Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markert

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
The Journal of Biological Chemistry|May 18, 2006
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cellsWanda H Vila-Carriles, Gergely Gy Kovacs, Biljana Jovov, et al.
The Journal of Biological Chemistry|February 14, 2003
Acid-sensing ion channels in malignant gliomasBakhrom K Berdiev, Jiazeng Xia, Lee Anne McLean, et al.
Cancer Gene Therapy|March 29, 2019
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceJoshua D Bernstock, Nunzio Vicario, Rong Li, et al.
Neurosurgical Focus|February 1, 2021
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomasNidal B Omar, R Timothy Bentley, David K Crossman, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K Friedman, Elizabeth A Beierle, George Yancey Gillespie, et al.
Scientific Reports|October 9, 2021
Author Correction: Positron emission tomography imaging with <sup>89</sup>Zr-labeled anti-CD8 cys-diabody reveals CD8<sup>+</sup> cell infiltration during oncolytic virus therapy in a glioma murine modelBenjamin B Kasten, Hailey A Houson, Jennifer M Coleman, et al.
Scientific Reports|July 29, 2021
Positron emission tomography imaging with <sup>89</sup>Zr-labeled anti-CD8 cys-diabody reveals CD8<sup>+</sup> cell infiltration during oncolytic virus therapy in a glioma murine modelBenjamin B Kasten, Hailey A Houson, Jennifer M Coleman, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Journal of Virology|March 2, 2012
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12James M Markert, James J Cody, Jacqueline N Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2022
Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB StudyKatherine E Miller, Kevin A Cassady, Justin C Roth, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
The Journal of Biological Chemistry|May 18, 2006
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cellsWanda H Vila-Carriles, Gergely Gy Kovacs, Biljana Jovov, et al.
The Journal of Biological Chemistry|February 14, 2003
Acid-sensing ion channels in malignant gliomasBakhrom K Berdiev, Jiazeng Xia, Lee Anne McLean, et al.
Cancer Gene Therapy|March 29, 2019
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of miceJoshua D Bernstock, Nunzio Vicario, Rong Li, et al.
Neurosurgical Focus|February 1, 2021
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomasNidal B Omar, R Timothy Bentley, David K Crossman, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K Friedman, Elizabeth A Beierle, George Yancey Gillespie, et al.
Scientific Reports|October 9, 2021
Author Correction: Positron emission tomography imaging with <sup>89</sup>Zr-labeled anti-CD8 cys-diabody reveals CD8<sup>+</sup> cell infiltration during oncolytic virus therapy in a glioma murine modelBenjamin B Kasten, Hailey A Houson, Jennifer M Coleman, et al.
Scientific Reports|July 29, 2021
Positron emission tomography imaging with <sup>89</sup>Zr-labeled anti-CD8 cys-diabody reveals CD8<sup>+</sup> cell infiltration during oncolytic virus therapy in a glioma murine modelBenjamin B Kasten, Hailey A Houson, Jennifer M Coleman, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Journal of Virology|March 2, 2012
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12James M Markert, James J Cody, Jacqueline N Parker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2022
Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB StudyKatherine E Miller, Kevin A Cassady, Justin C Roth, et al.
Pageof 27